|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence
|
|
Ali Nasrallah, MD
|
| Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system.
|
|
|
|
|
|
|
|
|
|
|
|
| Harnessing Artificial Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment |
| David McConkey, PhD |
| David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and industry partners to develop and validate AI tools for cancer diagnosis and treatment prediction. |
|
|
|
|
|
|
|
|
|
|
|
| Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial |
| Neal Shore, MD, FACS |
| Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. |
|
|
|
|
|
|
|
|
|
|
|
| SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer |
| Stephen B. Williams, MD, MS, FACS |
| Sam Chang and Stephen Williams discuss the ongoing SunRISe-2 trial, a phase three study targeting muscle-invasive bladder cancer (MIBC). Dr. Williams details the trial's innovative approach using TAR-200, a device for sustained gemcitabine release directly into the bladder, combined with cetrelimab, a PD-1 antibody. |
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer Recurrence Analysis in Veterans and Outcomes (BRAVO): White Light Versus Blue Light Cystoscopy Outcomes Among NMIBC Patients in an Equal Access Setting |
| Ali Nasrallah, MD |
| Ali Nasrallah presented the BRAVO study, which compared the outcomes of white light versus blue light cystoscopy in non-muscle invasive bladder cancer (NMIBC) patients within the Veterans Affairs Healthcare System. The study of 740 patients found that blue light cystoscopy was associated with a significantly reduced risk of bladder cancer recurrence at 3 years (HR 0.62), although progression risk was similar between the two groups. |
|
|
|
|
|
| Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression |
| Bishoy Faltas, MD |
| Bishoy Faltas presented an innovative multimodal deep learning model aimed at predicting pathologic complete response (pCR) in muscle invasive bladder cancer (MIBC) patients undergoing neoadjuvant chemotherapy. The model integrates three types of data: histopathology (via H&E whole-slide imaging), gene expression (RNA), and cell type morphology. |
|
|
|
|
|
|
|
|
|
|
| Prospective Evaluation of BCG Unresponsive Bladder Cancer CIS Identifies Genetic Mechanisms of Immunotherapy Resistance and Targeted Therapy using an Ultra-Sensitive Next Generation Sequencing Minimal Residual Disease Assay |
| Joshua Meeks, MD, PhD |
| Joshua Meeks presented a prospective study using an ultra-sensitive next-generation sequencing (NGS) minimal residual disease assay to identify genetic mechanisms of immunotherapy resistance in BCG-unresponsive carcinoma in situ (CIS) bladder cancer. The study found that most patients with BCG-unresponsive CIS began salvage therapy with detectable minimal residual disease, with subsequent tumor fraction decline. |
|
|
|
|
|
| The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer |
| Andrea Necchi, MD |
| Andrea Necchi highlights the role of multi-parametric MRI (mpMRI) in muscle-invasive bladder cancer (MIBC) management, emphasizing its evolving use for staging, assessing treatment response, and identifying patients suitable for bladder-sparing strategies. Dr. Necchi discusses advancements like the VI-RADS scoring system and the nacVI-RADS framework, which help predict response to neoadjuvant therapies, particularly in combination with biomarkers. |
|
|
|
|
|
| Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy |
| Lourdes Mengual, PhD |
| Lourdes Mengual presents findings on the use of circulating tumor DNA (ctDNA) as a dynamic biomarker for predicting prognosis in muscle-invasive bladder cancer (MIBC) patients following radical cystectomy. The study involved two cohorts: one using tumor-informed testing and the other a tumor-agnostic approach. Results showed that ctDNA status, particularly four months post-surgery, was a strong predictor of cancer progression and survival, with changes in ctDNA levels providing earlier indications of recurrence compared to imaging. |
|
|
|
|
|
